KR102921718B1 - 전립선암 검출 및 치료 방법 - Google Patents

전립선암 검출 및 치료 방법

Info

Publication number
KR102921718B1
KR102921718B1 KR1020207026864A KR20207026864A KR102921718B1 KR 102921718 B1 KR102921718 B1 KR 102921718B1 KR 1020207026864 A KR1020207026864 A KR 1020207026864A KR 20207026864 A KR20207026864 A KR 20207026864A KR 102921718 B1 KR102921718 B1 KR 102921718B1
Authority
KR
South Korea
Prior art keywords
tmprss2
prostate cancer
score
subject
cutoff value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207026864A
Other languages
English (en)
Korean (ko)
Other versions
KR20200123450A (ko
Inventor
마크 키드
아이그넛 드로즈도브
어빈 마크 모들린
Original Assignee
리퀴드 바이옵시 리서치 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리퀴드 바이옵시 리서치 엘엘씨 filed Critical 리퀴드 바이옵시 리서치 엘엘씨
Priority to KR1020267002939A priority Critical patent/KR20260018206A/ko
Publication of KR20200123450A publication Critical patent/KR20200123450A/ko
Application granted granted Critical
Publication of KR102921718B1 publication Critical patent/KR102921718B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/143Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Databases & Information Systems (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)
  • Artificial Intelligence (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207026864A 2018-02-22 2019-02-21 전립선암 검출 및 치료 방법 Active KR102921718B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020267002939A KR20260018206A (ko) 2018-02-22 2019-02-21 전립선암 검출 및 치료 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862633675P 2018-02-22 2018-02-22
US62/633,675 2018-02-22
PCT/US2019/018878 WO2019165021A1 (en) 2018-02-22 2019-02-21 Methods for prostate cancer detection and treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020267002939A Division KR20260018206A (ko) 2018-02-22 2019-02-21 전립선암 검출 및 치료 방법

Publications (2)

Publication Number Publication Date
KR20200123450A KR20200123450A (ko) 2020-10-29
KR102921718B1 true KR102921718B1 (ko) 2026-02-03

Family

ID=65686083

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207026864A Active KR102921718B1 (ko) 2018-02-22 2019-02-21 전립선암 검출 및 치료 방법
KR1020267002939A Pending KR20260018206A (ko) 2018-02-22 2019-02-21 전립선암 검출 및 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020267002939A Pending KR20260018206A (ko) 2018-02-22 2019-02-21 전립선암 검출 및 치료 방법

Country Status (15)

Country Link
US (3) US11410748B2 (https=)
EP (2) EP3755816B1 (https=)
JP (2) JP7662337B2 (https=)
KR (2) KR102921718B1 (https=)
CN (2) CN119932188A (https=)
AU (2) AU2019224025B2 (https=)
BR (1) BR112020016989A2 (https=)
CA (1) CA3091647A1 (https=)
DK (1) DK3755816T3 (https=)
ES (1) ES3023842T3 (https=)
IL (1) IL276748A (https=)
MX (2) MX2020008702A (https=)
PL (1) PL3755816T3 (https=)
SG (1) SG11202007922XA (https=)
WO (1) WO2019165021A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022004372A (es) 2019-10-10 2022-07-27 Liquid Biopsy Res Llc Composiciones, métodos y kits para la estabilización de muestras biológicas y de arn.
EP4100955A4 (en) * 2020-02-06 2024-02-28 Oncohost Ltd MACHINE LEARNING PREDICTION OF THERAPEUTIC RESPONSE
CA3227993A1 (en) 2021-08-11 2023-02-16 OncoHost Ltd. Predicting patient response
EP4602184A1 (en) * 2022-10-12 2025-08-20 Liquid Biopsy Research LLC Methods for prostate cancer detection in saliva
GB2623570B (en) * 2022-10-21 2025-07-23 Wobble Genomics Ltd Method and products for biomarker identification
KR102891032B1 (ko) * 2022-12-29 2025-12-03 재단법인대구경북과학기술원 혈액 단구세포 전사체 생체표지자를 이용한 전이성 전립선암 진단용 바이오마커 및 이의 용도
CN116908444B (zh) * 2023-09-13 2023-12-19 中国医学科学院北京协和医院 血浆max自身抗体在晚期非小细胞肺癌pd-1单抗联合化疗治疗预后预测中的应用
CN119964650B (zh) * 2024-12-24 2025-09-30 深圳大学 一种基于集成学习的基因调控网络推断方法和系统

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009540852A (ja) * 2006-07-03 2009-11-26 エグゾニ・テラピューティック・ソシエテ・アノニム 前立腺特異的な転写物ならびに前立腺癌の治療および診断におけるその使用
US20100303795A1 (en) * 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
MX338883B (es) * 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
US8725426B2 (en) 2012-01-31 2014-05-13 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
CA2879557A1 (en) * 2012-07-20 2014-01-23 Diagnocure Inc. Methods, kits and compositions for providing a clinical assessment of prostate cancer
EP2882869A4 (en) * 2012-08-07 2016-04-20 Jackson H M Found Military Med PROSTATE CANCER GENE EXPRESSION PROFILE
US10431326B2 (en) * 2012-11-20 2019-10-01 Phadia Ab Method for indicating a presence or non-presence of aggressive prostate cancer
SG10201907684PA (en) * 2013-01-15 2019-10-30 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
CN105209636A (zh) * 2013-03-15 2015-12-30 麦塔马克基因股份有限公司 用于癌症预后的组合物和方法
EP3800266A1 (en) * 2013-06-13 2021-04-07 University Of South Australia Methods for detecting prostate cancer
AU2014305994B2 (en) * 2013-08-06 2019-02-21 Exosome Diagnostics, Inc. Urine biomarker cohorts, gene expression signatures, and methods of use thereof
EP3214444A1 (en) 2016-03-04 2017-09-06 AIT Austrian Institute of Technology GmbH Prostate cancer diagnostic method and means

Also Published As

Publication number Publication date
AU2019224025A1 (en) 2020-09-10
SG11202007922XA (en) 2020-09-29
IL276748A (en) 2020-10-29
WO2019165021A1 (en) 2019-08-29
CN112673115A (zh) 2021-04-16
US20260066046A1 (en) 2026-03-05
JP2021514624A (ja) 2021-06-17
US20190259471A1 (en) 2019-08-22
KR20200123450A (ko) 2020-10-29
EP4538393A2 (en) 2025-04-16
MX2025000449A (es) 2025-03-07
PL3755816T3 (pl) 2025-06-30
JP2025096376A (ja) 2025-06-26
CN119932188A (zh) 2025-05-06
KR20260018206A (ko) 2026-02-06
JP7662337B2 (ja) 2025-04-15
CA3091647A1 (en) 2019-08-29
MX2020008702A (es) 2020-09-25
BR112020016989A2 (pt) 2020-12-29
AU2025238057A1 (en) 2025-11-27
EP3755816B1 (en) 2025-02-12
EP4538393A3 (en) 2025-07-02
EP3755816A1 (en) 2020-12-30
US11410748B2 (en) 2022-08-09
DK3755816T3 (da) 2025-04-28
CN112673115B (zh) 2025-02-18
US20230298695A1 (en) 2023-09-21
ES3023842T3 (en) 2025-06-03
AU2019224025B2 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
AU2019201577B2 (en) Cancer diagnostics using biomarkers
KR102921718B1 (ko) 전립선암 검출 및 치료 방법
AU2015334841B2 (en) Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
AU2018210695B2 (en) Molecular subtyping, prognosis, and treatment of bladder cancer
AU2015334842B2 (en) Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
AU2017267184B2 (en) Method for assessing a prognosis and predicting the response of patients with malignant diseases to immunotherapy
RU2719194C2 (ru) Оценка активности клеточных сигнальных путей с применением вероятностного моделирования экспрессии целевых генов
RU2721130C2 (ru) Оценка активности путей клеточной сигнализации с помощью линейной комбинации(ий) экспрессий генов-мишеней
KR102023584B1 (ko) 위장관췌장 신경내분비 신생물 (GEP-NENs)의 예측 방법
AU2016331663B2 (en) Pathogen biomarkers and uses therefor
AU2017343779A1 (en) Compositions and methods for predicting response and resistance to CTLA4 blockade in melanoma using a gene expression signature
KR20120082906A (ko) 자가포식현상-향상 유전자 생성물의 조절을 통한 자가포식현상의 조절 방법
WO2003042661A2 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2021183218A1 (en) Compositions and methods for modulating the interaction between ss18-ssx fusion oncoprotein and nucleosomes
CN101573453A (zh) 使用生物学途径基因表达分析来预测淋巴结阴性原发性乳腺癌的远处转移的方法
CN101258249A (zh) 检测黑素瘤的方法和试剂
JP2003304888A (ja) 化合物の毒性予測のための方法
KR20200113237A (ko) 결장암 검출 및 치료 모니터링을 위한 방법
KR20040065524A (ko) 백혈병을 검사 및 치료하는 방법
CN114127314A (zh) 用于对乳腺癌的亚型(Subtype)进行鉴别或者分类的鉴别标志物遗传基因组、方法和套件
KR102785072B1 (ko) 형질 세포 질환의 검출 방법
KR20060045950A (ko) 혈액학적 악성종양에 대한 예후
US20020137077A1 (en) Genes regulated in activated T cells
KR20070099564A (ko) 급성 골수성 백혈병 환자를 평가하는 방법
KR102046839B1 (ko) 대장암의 시험관내 진단 또는 예후 예측 방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)